Dr Craske circulated a prospective study protocol. Any haemophilia centre directors could use the protocol when evaluating any new concentrate products; directors would be invited to report the results in a standardised way to the UKHCDs Hepatitis Working Party and to retain serial samples of each patient's serum so a collection would be available to evaluate any new marker tests for NANBH.